# A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

> **NCT01959529** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 7637 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT01959529
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-29
- **Primary completion:** 2016-10-16
- **Final completion:** 2016-10-16
- **Target enrollment:** 7637 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959529, "A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01959529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*